Impacting ALS, a collaboration between HudsonAlpha Institute for Biotechnology and the Crestwood ALS Care Clinic, a Treatment Center of Excellence.
As many as 20,000 Americans live with ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease, and 15 new cases are diagnosed in this country every day. This devastating disease, which causes the progressive loss of a person’s ability to move, breathe, swallow, write and speak, has no cure.
In collaboration with Crestwood ALS Care Clinic, a National ALS Association Treatment Center of Excellence in Huntsville, Ala., HudsonAlpha Institute for Biotechnology is launching Impacting ALS. HudsonAlpha scientists will conduct genomic sequencing and analysis of ALS patients to better understand the underlying cause of the disease.
Utilizing cutting-edge technology and genomics expertise, scientists are working to untangle ALS and other neurodegenerative diseases to identify better treatments for these conditions.
“A diagnosis helps, but we really need to find treatments for these diseases,” said Rick Myers, PhD, HudsonAlpha president and science director.
Your financial assistance with Impacting ALS helps HudsonAlpha continue its push toward a better treatment. Your gift today gives hope.
The HudsonAlpha Foundation, a 501(c)(3) nonprofit organization, is the supporting entity for the HudsonAlpha Institute for Biotechnology. Tax-deductible contributions to the foundation are for the sole purpose of advancing the mission of the HudsonAlpha Institute for Biotechnology.
Tax identification #27-2320591